Connect
MJA
MJA

Survival studies: competing risks, immortality and censoring

Adrian G Barnett, Christopher Oldmeadow and John R Attia
Med J Aust 2018; 208 (11): 475-477. || doi: 10.5694/mja17.00171
Published online: 18 June 2018

One of the simplest study designs is giving participants — with a headache, for example — an active pill or placebo at random and then observing their outcome of cured or not cured one hour later. Studies with such short time frames are rare, and meaningful outcomes, such as disease or death, often need to be followed up long after the initial contact, potentially decades later.

  • Adrian G Barnett1
  • Christopher Oldmeadow2
  • John R Attia2,3

  • 1 Institute of Health and Biomedical Innovation and School of Public Health and Social Work, Queensland University of Technology, Brisbane, QLD
  • 2 Centre for Clinical Epidemiology and Biostatistics, University of Newcastle, Newcastle, NSW
  • 3 John Hunter Hospital, Newcastle, NSW

Correspondence: a.barnett@qut.edu.au

Acknowledgements: 

Adrian Barnett is supported by a National Health Medical Research Council Senior Research Fellowship (APP1117784).

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.